CSIMarket Company Name, Ticker, Competitors, else..
 
Cyteir Therapeutics Inc   (NASDAQ: CYT)
Other Ticker:  
 
 
Price: $3.0200 $-0.07 -2.265%
Day's High: $3.09 Week Perf: -0.33 %
Day's Low: $ 3.00 30 Day Perf: -3.21 %
Volume (M): 1,007 52 Wk High: $ 0.00
Volume (M$): $ 3,041 52 Wk Avg: $0.00
Open: $3.03 52 Wk Low: $0.00



 Market Capitalization (Millions $) 109
 Shares Outstanding (Millions) 36
 Employees 98
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 0

Cyteir Therapeutics Inc
Cyteir Therapeutics Inc is a clinical-stage biotechnology company that focuses on developing novel small molecule drugs that target DNA damage response pathways for cancer treatment. The company was founded in 2013 and is headquartered in Lexington, Massachusetts.

The main objective of Cyteir Therapeutics is to improve the effectiveness of cancer treatment by exploiting the therapeutic potential of DNA damage response pathways. Their innovative approach aims to selectively exploit the DNA repair machinery that cancer cells need to survive, leading to improved efficacy and reduced toxicity in cancer treatment.

The company's lead drug candidate, CYT-0851, is an orally administered therapy that inhibits RAD51, a protein that plays a crucial role in DNA repair processes. This drug is currently undergoing clinical trials for the treatment of solid tumors such as ovarian and breast cancer.

Apart from CYT-0851, Cyteir also has other promising drug candidates in the pipeline that target DNA damage response pathways. These drug candidates have the potential to become game-changers in cancer treatment by offering a personalized approach to patients based on their individual genetic profiles.

Cyteir is backed by leading venture capital firms such as Novartis Venture Fund, Venrock, and Lightstone Ventures. The company has also secured substantial funding from the National Cancer Institute and other organizations to support its research efforts.

Overall, Cyteir Therapeutics is a pioneering biotech company that is leading the charge in the development of innovative cancer therapeutics that target DNA damage response pathways. With a strong and experienced management team, cutting-edge technology, and promising drug candidates in the pipeline, Cyteir is well-positioned to make a significant impact in the fight against cancer.


   Company Address: 99 Hayden Ave., Building B Lexington 2421 MA
   Company Phone Number: 285-4140   Stock Exchange / Ticker: NASDAQ CYT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BPMC   -3.71%    
DCPH        0.08% 
ICPT        0.21% 
MGNX   -8.49%    
RIGL   -3.95%    
SUPN   -0.03%    
• View Complete Report
   



Cyteir Therapeutics Inc

Cyteir Therapeutics Inc. Makes Waves in Biotech Industry with Surprising Q3 Numbers



The Major Pharmaceutical Preparations sector is abuzz with analysts closely examining the third-quarter numbers of Cyteir Therapeutics Inc. This up-and-coming biotech company has managed to captivate investors' attention with its impressive improvements in operating efficiency.
The recently released Q3 2023 report reveals that Cyteir Therapeutics Inc has successfully reduced its operating shortfall to $-5.171 million, a significant improvement from the previous year's $-11.759 million loss. As the company has not declared any revenue yet, investors are focusing solely on its ability to manage expenses effectively.
Cyteir Therapeutics Inc

Cyteir Therapeutics Weathering the Storm: Reports Reduced Operating Deficit in Q2 2023



Cyteir Therapeutics Inc, a rising biopharmaceutical company, recently released its financial results for the fiscal period ending June 30, 2023. While stockholders may have anticipated a moderation in revenue, the company's operating deficit decreased significantly, indicating improved cost-effectiveness. This article aims to analyze the implications of these financial results on Cyteir Therapeutics Inc's future prospects.
1. Decreasing Operating Deficit:
One of the key takeaways from Cyteir Therapeutics Inc's financial report is the progressive reduction in operating deficit. In the fiscal period ending June 30, 2022, the company reported a concerning operating deficit of $-12.227 million. However, the executives managed to curtail losses, bringing the operating deficit down to $-8.404 million in the subsequent fiscal period ending June 30, 2023. This reduction reflects the company's commitment to controlling costs and optimizing its operations.
Cyteir Therapeutics Inc

Surprising First Quarter Shortfall Sends Shockwaves through Cyteir Therapeutics Inc - What's Next for the Major Pharmaceutical Preparations Leader?

Cyteir Therapeutics Inc, a Massachusetts-based clinical stage biotechnology company, reported a net loss of -$44 million for the 12 months ending in the first quarter of 2023, resulting in a negative return on equity (ROE) of -29.68%. This figure indicates that the company experienced a loss in shareholder value during this period.
Comparatively, within the Major Pharmaceutical Preparations industry, 77 other companies recorded a higher ROE than CYT. While this may seem concerning, it's important to note that CYT is still considered an emerging business and was only founded in 2013.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com